—

Kiniksa Pharmaceuticals Ltd (KNSA) — the peer cohort

As of 2026-10-09 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Kiniksa Pharmaceuticals Ltd ranks 6 of 11 in its cohort on the Closelooknet composite (56/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
KNSA Kiniksa Pharmaceuticals Ltd 56 94 57 21 ok 3.8%
LNTH Lantheus Holdings Inc 59 68 72 57 info 10.5%
BHC.TO Bausch Health Companies Inc 55 65 70 84 info 22%
AMRX Amneal Pharmaceuticals, Inc. Class A Common Stock 54 89 56 42 ok 6%
GALDY GALDERMA GROUP AG 54 45 57 27 info 14.1%
ALM.MC Almirall S.A. 53 22 44 69 warn 26.9%
FAGR.BR Fagron NV 52 40 54 61 info 12.3%
HALO Halozyme Therapeutics Inc 74 93 94 51 ok 5.5%
DXCM DexCom Inc 66 81 80 38 watch 8.8%
ONC BeiGene, Ltd. 63 77 62 32 info 8%
MEDP Medpace Holdings Inc 63 84 74 30 ok 9.7%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-09

Quick answers

Who are Kiniksa Pharmaceuticals Ltd's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Lantheus Holdings Inc (LNTH), Bausch Health Companies Inc (BHC.TO), Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX), GALDERMA GROUP AG (GALDY), Almirall S.A. (ALM.MC), Fagron NV (FAGR.BR), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM) and others.

How does KNSA score against its peers?

Kiniksa Pharmaceuticals Ltd's composite reads 56/100, ranking 6 of 11 in its cohort as of 2026-10-09; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.